Acutus Medical (OTC:AFIB) Stock, Quote.Headers.trade-ideas

Acutus Medical

Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping, and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Outside the United States.

xr:d:DAFih-sWqhI:2,j:46865321670,t:23051015

News

Intraday Update

Markets

Movers

AFIB

AFRM

ALAB

AMRC

AMRK

AOSL

APEI

ARKO

BROS

CLOV

CPNG

CRCT

CRUS

DTCK

ELAN

FLYW

GMED

Hannon Armstrong Sustainable Infrastructure Capital

HASI

INOD

INSP

ISUN

LAZR

LYFT

MASI

MCRB

MXCT

MYGN

NIVF

PWSC

QLYS

REBN

RPTX

SATS

SHLS

SHOP

SIGA

SMLR

STAA

SWIM

TEVA

TIVC

TMCI

TOST

TRIP

TWLO

UBER

UPST

VECO

VLCN

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

xr:d:DAFq8R_nQ7g:2,j:6031844861216095376,t:23080809

Pre-Market Outlook

Trading Ideas

RDDT

WETH

Why RingCentral Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

ACMR

ALHC

ALPN

AUGX

BTDR

BYND

CJET

CLSK

CMTL

COIN

CRNX

DCGO

DRCT

ELVN

ENVB

FUSN

GWAV

HOTH

HUYA

JOAN

LICY

MARA

MBTC

MNPR

MSTR

NCMI

OTRK

PIXY

PRSO

PRTG

SEEL

SMCI

SOUN

SPIR

STNE

SWIN

VERB

WORX

ZCAR

ZEPP

Shares of  Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

ACUTUS MEDICAL INC by Acutus Medical Inc.

Acutus Medical Inc

Former White House Communications Director Anthony Scaramucci humorously thanked Donald Trump's <a href="https://www.benzinga.com/general/politics/24/07/39780777/trump-picks-senator-j-d-vance-as-running-mate-musk-says-great-choice-for-vp">running mate</a>, JD Vance (R-Ohio), for taking his place as the worst hire of the former president.
What Happened: Scaramucci expressed his gratitude to Vance for ousting him from the position of the worst Trump hire, in a post on Friday on social media platform X, formerly Twitter.
&#8220;I just want to personally thank JD Vance for knocking me out of the position of the worst Donald Trump hire. I didn't think it would happen but here we are and I am grateful.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I just want to personally thank <a href="https://twitter.com/JDVance?ref_src=twsrc%5Etfw">@JDVance</a> for knocking me out of the position of the worst Donald Trump hire. I didn't think it would happen but here we are and I am grateful. &#x1f64f;
&mdash; Anthony Scaramucci (@Scaramucci) <a href="https://twitter.com/Scaramucci/status/1816928720894169307?ref_src=twsrc%5Etfw">July 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/23/11/35952778/former-doj-attorney-calls-marjorie-taylor-greenes-new-book-score-settling-fiction-that-reads-like-an?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Ex-DOJ Attorney Calls Marjorie Taylor Greene&#8217;s New Book &#8216;Score-Settling Fiction&#8217;</a>
Scaramucci&#8217;s post comes amidst <a href="https://www.benzinga.com/news/24/07/39979544/can-trump-replace-jd-vance-amid-kamala-harris-picking-pace-experts-warn-that-could-be-extraordinaril">growing speculation</a> about Vance&#8217;s position as Trump&#8217;s Vice Presidential candidate due to his underwhelming polling and the rising momentum of Vice President Kamala Harris.
Why It Matters: Scaramucci has been vocal about his disapproval of Vance as Trump&#8217;s running mate. He <a href="https://www.benzinga.com/news/24/07/39854646/anthony-scaramucci-says-jd-vances-quest-to-wall-us-off-from-rest-of-world-could-be-an-economic-disas">previously stated</a> that Vance&#8217;s economic policies could lead to a disaster for the United States and the world.
He also <a href="https://www.benzinga.com/news/24/07/39787296/first-obvious-error-by-trump-after-winning-nomination-says-anthony-scaramucci-of-ex-president-picks">criticized</a> Trump&#8217;s decision to pick Vance as his running mate, calling it the &#8220;first obvious error&#8221; by Trump after winning the nomination.
Vance has also <a href="https://www.benzinga.com/news/24/07/39784888/aoc-mocks-trump-vp-choice-j-d-vance-for-tweet-connecting-fertility-rate-with-daylight-saving-time">come under criticism</a> for his past social media activity, with Rep.&nbsp;Alexandria Ocasio-Cortez&nbsp;(D-N.Y.) highlighting a post made by Trump's running mate linking fertility rates with daylight savings time.
Vance reportedly wrote on November 1, 2020: "As a parent of young children and a nationalist who worries about America's low fertility I can say with confidence that daylight savings time reduces fertility by at least 10 percent."
Vance later said this post was a joke.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/01/36877020/robert-f-kennedy-jr-doesnt-want-to-be-trumps-vice-president-pick-heres-why?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Robert F. Kennedy Jr. Doesn&#8217;t Want To Be Trump&#8217;s Vice President Pick, Here&#8217;s Why</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Al Teich on Shutterstock

Politics

Former White House Official Anthony Scaramucci Mocks JD Vance, Says Thank You For 'Knocking Me Out Of The Position Of The Worst Donald Trump Hire'

Deepwater Asset Management&#8217;s managing partners, Gene Munster and Doug Clinton have <a href="https://www.businessinsider.in/tech/news/openais-new-searchgpt-prototype-is-a-declaration-of-war-against-google/articleshow/112024630.cms">downplayed concerns</a> that Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Search could be outdone by OpenAI&#8217;s SearchGPT.
What Happened: On Friday, Munster took to X, formerly Twitter, and said, &#8220;Since it&#8217;s only a 15-second video, it&#8217;s hard to see why SearchGPT is 10x better than Google AI Overviews.&#8221;
He went on to say that in the near term, this revives fears among Google investors that AI could threaten search. However, if the product&#8217;s capabilities are limited to what&#8217;s shown in the teaser, Google is not in any significant danger.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39922283/elon-musk-is-polling-x-and-asking-if-tesla-should-invest-5b-in-grok-parent-xai-this-is-just-to-test?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Is Polling X And Asking If Tesla Should Invest $5B In Grok Parent xAI: &#8216;This Is Just To Test The Waters&#8217;</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Since its only a 15 second video, it&#39;s hard to see why SearchGPT is 10x better than Google AI Overviews. Near-term this revive fears from <a href="https://twitter.com/search?q=%24GOOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOG</a> investors that AI can kill search. If this is the product, Google is not in any meaningful danger. <a href="https://t.co/YX4Qa4Smac">https://t.co/YX4Qa4Smac</a>
&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1816549429782151403?ref_src=twsrc%5Etfw">July 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Doug Clinton, the other managing partner at Deepwater, concurred with Munster&#8217;s views. He said that although the SearchGPT video resulted in a minor dip in Google&#8217;s stock, it does not pose a substantial threat to Google&#8217;s AI.
&#8220;It didn&#8217;t seem 10x superior to what I&#8217;m observing&nbsp;from Google and AI overviews,&#8221; Clinton remarked in a separate video.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">On this week&#39;s DeepTech315, <a href="https://twitter.com/dougclinton?ref_src=twsrc%5Etfw">@dougclinton</a> and I discuss <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> and <a href="https://twitter.com/search?q=%24GOOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOG</a> earnings, and OpenAI&#39;s new search product, SearchGPT. <a href="https://t.co/9cGt75OwAu">pic.twitter.com/9cGt75OwAu</a>
&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1816565516309295351?ref_src=twsrc%5Etfw">July 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Both partners concurred that unless SearchGPT can offer something unique or more than what was shown in the teaser, it&#8217;s difficult to see why users would switch from Google.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: On Thursday, Alphabet shares were trading lower after a <a href="https://www.benzinga.com/news/24/07/39968522/alphabet-stock-falls-as-openai-plans-searchgpt-what-investors-need-to-know">report suggested that OpenAI plans</a> to launch an online search tool called &#8220;SearchGPT&#8221; to disrupt Google's Search dominance.
Soon after, ChatGPT-parent, announced that it is testing SearchGPT, a temporary prototype of new AI search features. The launch is initially limited to a small group of users for feedback, with plans to integrate the experience into ChatGPT, the company stated.
Price Action: At the time of writing, Alphabet's Class A shares were down by 0.072% in after-hours trading to $166.88, while Class C shares dropped 0.018% to $168.65. During the regular session, Class A and Class C shares had closed at $167 and $168.68, respectively, according to<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">&nbsp;Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39929189/elon-musk-agrees-with-mark-zuckerberg-on-apple-tesla-ceo-wonders-how-many-enemies-he-can-make-and-su?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Agrees With Mark Zuckerberg On Apple, Tesla CEO Wonders How Many Enemies He Can Make And Survive</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Google Photo by DenPhotos on Shutterstock

Tech

General

GOOG

GOOGL

Top Analyst Says OpenAI's AI-Powered Search Engine Likely Isn't A Threat To Google: 'It's Hard To See Why SearchGPT Is 10X Better…'

The much-anticipated initial public offering (IPO) of billionaire investor Bill Ackman&#8216;s Pershing Square closed-end fund has been postponed, as confirmed by the New York Stock Exchange (NYSE.)
What Happened: On Friday, the NYSE announced on its website that the listing of Pershing Square USA Ltd. has been delayed, with a new date yet to be disclosed. 
Pershing Square refrained from commenting further but issued a statement clarifying that the IPO is still proceeding, with the pricing date to be announced later.
See Also: <a href="https://www.benzinga.com/news/24/07/39947623/lindsey-graham-says-americans-are-struggling-and-our-country-is-heading-in-the-wrong-direction-repla?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lindsey Graham Says &#8216;Americans Are Struggling, And Our Country Is Heading In The Wrong Direction&#8217;</a>
The delay comes amid Ackman&#8217;s concerns about the size of the transaction and the novelty of the structure. He expressed these concerns in a July 24 letter to investors, emphasizing the need for careful analysis and judgment from investors.
The fund is expected to invest in 12 to 24 large-cap, investment-grade, &#8220;durable growth&#8221; companies in North America. The public listing is seen as a move to leverage Ackman&#8217;s following among Main Street investors.
Why It Matters: The IPO delay follows a <a href="https://www.benzinga.com/news/24/07/39975768/bill-ackmans-us-fund-ipo-target-slashed-by-90-as-pershing-square-specifically-disclaims-ceos-comment">significant reduction in the fund&#8217;s targe</a>t, which was slashed by as much as 90% from the initial $25 billion. In a letter to investors in his Pershing Square holding company sent on Wednesday, Ackman urged, "This is a moment when you can be very helpful to Pershing Square by participating in the PSUS offering and giving your order to the banks, the sooner the better." However, Pershing Square USA "specifically disclaims" Ackman's statement in the filing that included the letter.
Inspired by Warren Buffett&#8216;s career, <a href="https://www.benzinga.com/news/24/07/39766570/bill-ackman-says-his-unofficial-mentor-warren-buffett-inspired-him-to-take-pershing-square-funds-pub">Ackman decided to take his funds public.</a> He planned to use his social media presence and a Buffett-like annual meeting to bolster his new investment fund.
Pershing Square USA is a closed-end fund set to be listed on the New York Stock Exchange, investing in large, publicly traded stocks that Ackman and his team believe are undervalued. Ackman had previously informed investors that he expected the company to trade at a premium compared to the net assets it held.
Despite the reduction in the IPO target, Ackman remains optimistic about the fund's potential, particularly with the involvement of U.S. retail investors and the&nbsp;<a href="https://www.benzinga.com/news/24/07/39811552/from-warren-buffett-style-annual-meetings-to-social-media-strategy-heres-how-bill-ackman-plans-to-bo" target="_blank" rel="noreferrer noopener">support of institutional investors</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39964922/ron-desantis-says-florida-supreme-court-should-not-have-allowed-cannabis-legalization-initiative?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Ron DeSantis Says Florida Supreme Court Should &#8216;Not Have Allowed&#8217; Cannabis Legalization Initiative On Ballot</a></li>
</ul>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Harvard Association for Law and Business/ Tracy Tolf

IPOs

Bill Ackman's Warren Buffett-Inspired Strategy Hits A Snag? Pershing Square USA Delays IPO Indefinitely After Slashing Target By 90%

US Treasury Secretary Janet Yellen has strongly refuted allegations of manipulating the issuance of <a href="https://www.benzinga.com/topic/treasuries">Treasury securities</a>. These accusations were made by economist Nouriel Roubini who suggested that such manipulation was aimed at reducing real borrowing costs across the economy.
What Happened: Yellen dismissed Roubini&#8217;s argument that the Treasury had a strategy to ease financial conditions, in an <a href="https://www.bloomberg.com/news/articles/2024-07-26/yellen-rejects-roubini-claim-of-manipulation-in-treasuries">interview</a> with Bloomberg.
&#8220;I can assure you 100% that there is no such strategy. We have never, ever discussed anything of the sort,&#8221; Yellen said.
The paper, co-authored by Roubini and Stephen Miran, a former Treasury official under President Donald Trump, claimed that the Treasury&#8217;s actions in the fall of last year reduced 10-year Treasury yields by a quarter of a percentage point.
This is roughly equivalent to a full percentage point reduction in the Federal Reserve&#8217;s benchmark rate.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39948413/trump-era-white-house-official-anthony-scaramucci-says-kamala-harris-is-capable-and-has-a-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump-Era White House Official Anthony Scaramucci Says Kamala Harris Is Capable And Has A Great Team</a>
Joshua Frost, the Treasury&#8217;s assistant secretary for financial markets, defended the department&#8217;s actions, stating they were within market participants&#8217; expectations.
Yellen supported Frost&#8217;s statements, saying his speech provided the best explanation for the department&#8217;s approach.
Why It Matters: The allegations against Yellen come in the wake of a series of events that have put her in the spotlight.
Earlier this month, <a href="https://www.benzinga.com/government/24/07/39749545/trump-allies-slam-janet-yellen-for-manipulating-treasury-debt-auctions-to-improve-bidens-image">she was accused</a> by Republican lawmakers of manipulating Treasury debt auctions to stimulate the economy and enhance President Joe Biden‘s image. This latest development is a continuation of the scrutiny Yellen has been facing.
<a href="https://www.benzinga.com/government/24/05/38572650/janet-yellen-stands-up-for-feds-autonomy-as-trump-allies-plan-to-gain-more-control">Yellen also defended</a> the Federal Reserve&#8217;s political independence against attempts by Trump allies to undermine it.
In June, she <a href="https://www.benzinga.com/news/24/06/39348581/janet-yellen-dismisses-donald-trumps-proposal-to-replace-income-tax-with-tariffs-the-impact-would-be">publicly criticized Trump&#8217;s proposal</a> to replace parts of the U.S. income tax with increased tariffs on imported goods.
Later that month, she <a href="https://www.benzinga.com/government/24/06/39470021/janet-yellen-says-inflation-to-come-down-to-feds-2-target-by-2025-dismisses-possibility-of-us-recess">expressed confidence</a> in the American economy, dismissing the possibility of a recession and predicting that inflation would reach the Federal Reserve's 2% target by next year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/07/39992709/kamala-harris-will-certify-2024-election-results-shes-not-going-to-burn-the-system-down-in-order?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kamala Harris Will Certify 2024 Election Results: &#8216;She&#8217;s Not Going To Burn The System Down In Order To Save It'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Flickr

Treasuries

Economics

Janet Yellen Rejects Economist Roubini's And Trump-Era Official's Claims Of 'Manipulation' In Treasuries: 'We Have Never, Ever Discussed Anything Of The Sort'

Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google has severed its business ties with One Medical, a <a href="https://www.benzinga.com/topic/healthcare">primary healthcare provider</a> acquired by Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) for $3.9 billion.
What Happened: Google, previously One Medical&#8217;s largest business client, has decided to terminate its enterprise agreement with the healthcare company following Amazon&#8217;s acquisition of One Medical last year, <a href="https://www.businessinsider.com/google-drops-amazon-one-medical-2024-7">reported</a> Business Insider.
The agreement, which offered Google employees discounted or free One Medical memberships and operated One Medical care centers at some Google office locations, is set to expire at the end of 2024.
Google was an early supporter of One Medical and was its largest business customer for many years. Until 2020, One Medical disclosed that Google accounted for 10% of its net revenue.
In 2021, that dipped below 10%, and then One Medical stopped publicly sharing financials after Amazon acquired it.
See Also: <a href="https://www.benzinga.com/general/biotech/24/07/39940874/gileads-42-5k-priced-hiv-drug-could-be-made-at-just-40-annually-campaigners-urge-company-to-slash?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Gilead&#8217;s $42.5K Priced HIV Drug Could Be Made At Just $40 Annually</a>
A Google spokesperson confirmed to the publication that the existing relationship with One Medical is changing after 2024 but stressed that the decision has nothing to do with Amazon&#8217;s new ownership of the healthcare provider.
The existing One Medical centers on Google&#8217;s campus have already transitioned to Premise Health to provide more services like pharmacy, gynecology, and coordinated care on-site, the spokesperson added.
An Amazon spokesperson told Business Insider that Google employees and their dependents will continue to have One Medical memberships &#8220;sponsored&#8221; by their employer through the end of 2024.
Why It Matters: The termination of Google&#8217;s business relationship with One Medical comes amid significant changes within the healthcare provider.
In September, CEO Amir Dan Rubin <a href="https://www.benzinga.com/news/23/09/34166966/amazons-one-medical-ceo-departs-amid-significant-leadership-shift">stepped down</a> from One Medical after six years at the helm, a little over a year after Amazon&#8217;s acquisition.
This leadership shift was followed by <a href="https://www.benzinga.com/general/biotech/24/02/36971965/amazon-implements-major-job-cuts-in-one-medical-and-pharmacy-units-to-save-100m">major job cuts</a> in February, as part of a cost-saving initiative aiming to save One Medical $100 million.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39954971/apple-drops-from-3rd-to-6th-in-china-amid-intensifying-competition-huawei-shipments-surge-41-in-">Apple Drops From 3rd To 6th In China Amid Intensifying Competition, Huawei Shipments Surge 41% In Q2: Report</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Amazon

Health Care

AMZN

Google Cuts Ties With Amazon-Owned One Medical, But Clarifies It Is Not Due To E-Commerce Giant's $3.9B Acquisition

Following President Joe Biden&#8217;s decision to <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39885549/biden-withdraws-from-2024-race-what-that-means-for-solana-etf-prospects">withdraw from the 2024 presidential race</a>, a poll conducted by The Wall Street Journal indicates that former President Donald Trump has a slight edge over Vice President Kamala Harris.
What Happened: The poll <a href="https://www.wsj.com/politics/elections/harris-erases-trumps-lead-wsj-poll-finds-e286144d?mod=e2tw">results</a> published on Friday revealed that Trump has the support of 49% of registered voters, while Harris trails slightly behind with 47%. The WSJ poll, conducted from July 23-25, surveyed 1,000 registered voters with a margin of error&nbsp;of ±3.1 percentage points.
The latest poll also showed a significant rise in Harris&#8217;s favorability among registered voters, jumping 11 points to 46%. In comparison, Trump&#8217;s favorability was at 47% and Biden&#8217;s at 39%.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39925959/kim-jong-un-rejects-donald-trumps-friendship-claims-north-korea-says-we-do-not-care-expresses-nuclea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kim Jong Un Rejects Donald Trump&#8217;s Friendship Claims? North Korea Says &#8216;We Do Not Care,&#8217; Expresses Nuclear Readiness Amid Rising Tension With US</a>
In a ballot test featuring Robert F. Kennedy Jr. alongside other independent and third-party candidates, Harris secured 45% of the vote, while Trump received 44%. Kennedy garnered just 4%, and 5% of voters remained undecided. 
In the last poll, Biden trailed by six points in the multicandidate contest, the report noted.
Why It Matters: The&nbsp;<a href="https://www.benzinga.com/general/politics/24/07/39973800/trump-vs-harris-vice-president-gains-ground-lost-by-joe-biden-in-swing-states">race between Trump and Harris</a>&nbsp;is shaping up to be a close one, with Harris making up ground lost by Biden in head-to-head matchups against Trump. 
President Biden&#8217;s campaign was plagued by a lackluster debate performance and concerns about his age and mental fitness, leading to his withdrawal last week.
Since Biden&#8217;s exit, Harris has garnered several key endorsements from her party, experienced a surge in fundraising, and secured enough delegate commitments to secure the nomination.
Meanwhile, Trump has been&nbsp;<a href="https://www.benzinga.com/news/24/07/39947274/trump-takes-aim-at-kamala-harris-in-first-rally-post-bidens-exit-calls-her-a-radical-left-lunatic-vp">criticizing Harris</a>&nbsp;on immigration and inflation issues, labeling her as a &#8220;radical-left lunatic.&#8221;
There has also been speculation about whether Trump might&nbsp;<a href="https://www.benzinga.com/news/24/07/39979544/can-trump-replace-jd-vance-amid-kamala-harris-picking-pace-experts-warn-that-could-be-extraordinaril">replace his vice presidential candidate</a>, Sen. J.D. Vance, due to the latter&#8217;s underwhelming polling and Harris&#8217;s growing momentum. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39975168/nikki-haley-says-democrats-are-very-smart-to-put-in-a-younger-candidate-against-trump-but-kamala-har?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nikki Haley Says &#8216;Democrats Are Very Smart To Put In A Younger Candidate&#8217; Against Trump But Kamala Harris Is The &#8216;Weakest Candidate&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Media

Trump Vs. Harris: New Poll Shows Ex-President Leading Democratic Candidate By A Narrow Margin, But Vice President's Favorability Is Faring Better Than Biden

H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 2.77% on an annualized basis producing an average annual return of 15.37%. Currently, H&amp;R Block has a market capitalization of $7.95 billion. 
Buying $1000 In HRB: If an investor had bought $1000 of HRB stock 5 years ago, it would be worth $2,049.30 today based on a price of $56.95 for HRB at the time of writing.
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029438_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 16.62%. Currently, Apollo Global Management has a market capitalization of $69.51 billion. 
Buying $1000 In APO: If an investor had bought $1000 of APO stock 10 years ago, it would be worth $4,546.33 today based on a price of $122.16 for APO at the time of writing.
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029433_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

Citigroup analyst Atif Malik maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Buy and lowers the price target from $185 to $162.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Teradyne, Lowers Price Target to $162

During the last three months, 5 analysts shared their evaluations of Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. The average price target has stayed the same, reflecting a consistent view from analysts. 
<img src="https://www.benzinga.com/files/images/story/2024/1722027698_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Puma Biotechnology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Puma Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Puma Biotechnology compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Puma Biotechnology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Puma Biotechnology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PBYI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Puma Biotechnology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Puma Biotechnology</h2>
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
<h3>A Deep Dive into Puma Biotechnology's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Puma Biotechnology's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -17.07%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Puma Biotechnology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Puma Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of -9.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Puma Biotechnology's ROA excels beyond industry benchmarks, reaching -2.17%. This signifies efficient management of assets and strong financial health.
Debt Management: Puma Biotechnology's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.17, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PBYI

Where Puma Biotechnology Stands With Analysts

During the last three months, 10 analysts shared their evaluations of Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Lennox Intl, presenting an average target of $581.9, a high estimate of $675.00, and a low estimate of $517.00. This upward trend is apparent, with the current average reflecting a 7.66% increase from the previous average price target of $540.50.
<img src="https://www.benzinga.com/files/images/story/2024/1722027675_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Lennox Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$550.00</td>
<td>$517.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$675.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$572.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$610.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$517.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$575.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$570.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$520.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lennox Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lennox Intl compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Lennox Intl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Lennox Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LII/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lennox Intl analyst ratings.</a>
<h2>Delving into Lennox Intl's Background</h2>
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
<h3>Unraveling the Financial Story of Lennox Intl</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Lennox Intl showcased positive performance, achieving a revenue growth rate of 2.81% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Lennox Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 51.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lennox Intl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Lennox Intl's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.72, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Lennox Intl

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 10 years by 12.34% on an annualized basis producing an average annual return of 23.26%. Currently, Taiwan Semiconductor has a market capitalization of $837.03 billion. 
Buying $1000 In TSM: If an investor had bought $1000 of TSM stock 10 years ago, it would be worth $7,815.64 today based on a price of $161.40 for TSM at the time of writing.
<h3>Taiwan Semiconductor's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722027659_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Taiwan Semiconductor 10 Years Ago Would Be Worth This Much Today

Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 9.75% on an annualized basis producing an average annual return of 22.36%. Currently, Canadian Natural Res has a market capitalization of $73.53 billion. 
Buying $100 In CNQ: If an investor had bought $100 of CNQ stock 5 years ago, it would be worth $279.38 today based on a price of $34.42 for CNQ at the time of writing.
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722027654_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Canadian Natural Res Stock In The Last 5 Years

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1722027642_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Betterware de Mexico SAPI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Betterware de Mexico SAPI's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Betterware de Mexico SAPI's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Betterware de Mexico SAPI analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Betterware de Mexico SAPI: A Closer Look</h2>
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
<h3>A Deep Dive into Betterware de Mexico SAPI's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Betterware de Mexico SAPI's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 10.36%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Betterware de Mexico SAPI's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 19.7%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Betterware de Mexico SAPI's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.68%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 3.6, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWMX

Critical Insights From Betterware de Mexico SAPI Analyst Ratings: What You Need To Know

Canaccord Genuity analyst Dalton Baretto maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$22 to C$23.

TSX:MAG

Canaccord Genuity Maintains Buy on MAG Silver, Raises Price Target to C$23

Canaccord Genuity analyst Mike Mueller maintains Baytex Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTE#TSX">BTE</a>) with a Buy and raises the price target from C$6.25 to C$6.5.

TSX:BTE

Canaccord Genuity Maintains Buy on Baytex Energy, Raises Price Target to C$6.5

First Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCAP#NASDAQ">FCAP</a>) reported quarterly earnings of $0.85 per share. This is a 3.66 percent increase over earnings of $0.82 per share from the same period last year.

Earnings

FCAP

First Cap Q2 EPS $0.85 Up From $0.82 YoY

Asset Sales

Johnson Controls International: Purchase Deal Says Robert Bosch Will Pay Co Termination Fee Of $300M If Purchase Agreement Is Terminated

PayPal Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NYSE">PYPL</a>) short percent of float has fallen 4.83% since its last report. The company recently reported that it has 20.55 million shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PayPal Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PayPal Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PayPal Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PayPal Holdings's peer group average for short interest as a percentage of float is 5.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PYPL

How Is The Market Feeling About PayPal Holdings?

Owens-Corning's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) short percent of float has risen 10.34% since its last report. The company recently reported that it has 1.49 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Owens-Corning Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026716_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Owens-Corning has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Owens-Corning's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Owens-Corning's peer group average for short interest as a percentage of float is 4.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Owens-Corning's Recent Short Interest

Imminent Magic Catheter Approval Will Spike Stereotaxis Stock

Acutus Medical Non-GAAP EPS of -$0.52, revenue of $5.2M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday!



Moving stocks are earnings reports, public offerings, insider buying and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is rocketing more than 44% alongside heavy pre-market trading.</li>



<li>BioVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/bivi-stock-quote/">BIVI</a>) shares are soaring over 19% without any clear news this morning.</li>



<li>Heart Test Laboratories (NASDAQ:<a href="https://investorplace.com/stock-quotes/hscs-stock-quote/">HSCS</a>) stock is surging more than 17% with strong early morning trading.</li>



<li>Yoshitsu (NASDAQ:<a href="https://investorplace.com/stock-quotes/tklf-stock-quote/">TKLF</a>) shares are gaining close to 16% despite any apparent news this morning.</li>



<li>Flora Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/flgc-stock-quote/">FLGC</a>) stock is rising over 15% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317871899&amp;type=PDF&amp;symbol=FLGC&amp;cdn=5882e28b5f1d979fb6e3d46dd126c4e3&amp;companyName=Flora+Growth+Corp.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2023-11-15">alongside insider buying</a>.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are increasing more than 13% with its <a href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-snti/senti-biosciences/news/senti-biosciences-third-quarter-2023-earnings-eps-beats-expe">latest earnings release</a>.</li>



<li>Esports Entertainment (NASDAQ:<a href="https://investorplace.com/stock-quotes/gmbl-stock-quote/">GMBL</a>) stock is climbing over 13% with heavy early morning trading.</li>



<li>Acutus Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/afib-stock-quote/">AFIB</a>) shares are jumping more than 13% with strong trading today.</li>



<li>Isun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) stock is heading 13% higher with its <a href="https://www.nasdaq.com/press-release/isun-inc.-reports-third-quarter-2023-results-2023-11-14">most recent earnings release</a>.</li>



<li>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) shares are up over 12% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is crashing more than 46% as a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317850450&amp;type=PDF&amp;symbol=VLCN&amp;cdn=001b639a9f2126eaa0bf523d5e221ead&amp;companyName=Volcon+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2023-11-08">public offering goes into effect</a>. </li>



<li>Augmedix (NASDAQ:<a href="https://investorplace.com/stock-quotes/augx-stock-quote/">AUGX</a>) shares are diving over 27% after <a href="https://www.nasdaq.com/press-release/augmedix-announces-pricing-of-upsized-public-offering-of-6250000-shares-of-common">pricing a public offering</a>.</li>



<li>Kubient (NASDAQ:<a href="https://investorplace.com/stock-quotes/kbnt-stock-quote/">KBNT</a>) stock is plummeting more than 17% <a href="https://investorplace.com/2023/11/why-is-kubient-kbnt-stock-down-14-today/">as its delisting approaches</a>.</li>



<li>Velo3D (NYSE:<a href="https://investorplace.com/stock-quotes/vld-stock-quote/">VLD</a>) shares are taking an over 15% beating after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317871328&amp;type=PDF&amp;symbol=VLD&amp;cdn=8f1f75ec001d1505c7491375cf77935b&amp;companyName=Velo3D+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-11-15">adjusting its Q3 earnings report</a>.</li>



<li>Alpine 4 (NASDAQ:<a href="https://investorplace.com/stock-quotes/alpp-stock-quote/">ALPP</a>) stock is tumbling more than 14% on Thursday morning.</li>



<li>Gaucho Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/vino-stock-quote/">VINO</a>) shares are sliding over 13% this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is decreasing more than 13% today.</li>



<li>Siyata Mobile (NASDAQ:<a href="https://investorplace.com/stock-quotes/syta-stock-quote/">SYTA</a>) shares are falling over 12% after <a href="https://za.investing.com/news/siyata-mobile-earnings-missed-by-100-revenue-fell-short-of-estimates-2934605">missing estimates in Q3</a>. </li>



<li>Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) stock is slipping more than 12% as it comes off a recent rally.</li>



<li>Sadot (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdot-stock-quote/">SDOT</a>) shares closed out our pre-market stock movers down over 12% after <a href="https://finance.yahoo.com/news/sadot-group-inc-reports-third-213000334.html">missing EPS estimates in Q3</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-nov-16th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth watching this morning!



Moving stocks this morning are collaboration agreements, merger plans, earnings, public share offerings and more.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Tracon Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tcon-stock-quote/">TCON</a>) stock is rocketing more than 54% with heavy trading after announcing a <a href="https://www.nasdaq.com/market-activity/stocks/tcon/press-releases">product development platform agreement</a>.</li>



<li>LQR House (NASDAQ:<a href="https://investorplace.com/stock-quotes/lqr-stock-quote/">LQR</a>) shares are soaring over 46% after <a href="https://www.nasdaq.com/press-release/lqr-house-repurchases-1476355-shares-in-ongoing-share-buy-back-initiative-2023-11-20">revealing share repurchase data</a>. </li>



<li>Mountain Crest Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcaf-stock-quote/">MCAF</a>) stock is surging close to 43% as it <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317880079&amp;type=PDF&amp;symbol=MCAF&amp;cdn=72ab37bf3b408f565581d0c0c65a6ea6&amp;companyName=Mountain+Crest+Acquisition+Corp.+IV&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2023-11-20">moves forward with merger plans</a>.</li>



<li>Connect Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntb-stock-quote/">CNTB</a>) shares are gaining more than 26% after announcing an <a href="https://www.nasdaq.com/press-release/connect-biopharma-and-simcere-announce-exclusive-licensing-and-collaboration">exclusive licensing and collaboration agreement</a>.</li>



<li>Symbotic (NASDAQ:<a href="https://investorplace.com/stock-quotes/sym-stock-quote/">SYM</a>) stock is increasing over 22% alongside a <a href="https://finance.yahoo.com/news/symbotic-reports-2023-results-record-210000758.html">strong Q4 earnings report</a>.</li>



<li>Marpai (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrai-stock-quote/">MRAI</a>) shares are climbing more than 19% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317879635&amp;type=PDF&amp;symbol=MRAI&amp;cdn=93528add0cd2688d706c15aa396522f1&amp;companyName=Marpai+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2023-11-20">with insider buying</a>.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is rising over 19% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317880292&amp;type=PDF&amp;symbol=INVO&amp;cdn=e17d8040a594797e299f47c01eef3054&amp;companyName=INVO+BioScience+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-11-20">share exchange agreement</a>.</li>



<li>Mobiv Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/mobv-stock-quote/">MOBV</a>) shares are jumping more than 14% on Tuesday morning.</li>



<li>Renalytix (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnlx-stock-quote/">RNLX</a>) stock is getting an over 12% boost without any clear news.</li>



<li>Artivion (NYSE:<a href="https://investorplace.com/stock-quotes/aort-stock-quote/">AORT</a>) shares are up more than 11% on Tuesday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) stock is plummeting over 39% after announcing a <a href="https://www.nasdaq.com/press-release/reliance-global-group-inc.-announces-proposed-underwritten-public-offering-2023-11-20">proposed public share offering</a>.</li>



<li>MorphoSys (NASDAQ:<a href="https://investorplace.com/stock-quotes/mor-stock-quote/">MOR</a>) shares are diving nearly 25% alongside <a href="https://www.nasdaq.com/press-release/ad-hoc%3a-morphosys-phase-3-study-of-pelabresib-in-myelofibrosis-demonstrates">Phase 3 study results</a>.</li>



<li>Sibanye Stillwater (NYSE:<a href="https://investorplace.com/stock-quotes/sbsw-stock-quote/">SBSW</a>) stock is tumbling more than 23% on <a href="https://www.bloomberg.com/news/articles/2023-11-21/sibanye-loses-824-million-of-value-on-convertible-bond-sale">a convertible bond sale</a>.</li>



<li>Alzamend Neuro (NASDAQ:<a href="https://investorplace.com/stock-quotes/alzn-stock-quote/">ALZN</a>) shares are taking an almost 21% beating on Tuesday.</li>



<li>Nogin (NASDAQ:<a href="https://investorplace.com/stock-quotes/nogn-stock-quote/">NOGN</a>) stock is dropping close to 20% after a roughly 74% rally yesterday. </li>



<li>Galmed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/glmd-stock-quote/">GLMD</a>) shares are sliding nearly 19% after <a href="https://www.nasdaq.com/press-release/galmed-announces-a-delay-in-the-initiation-of-its-primary-sclerosing-cholangitis-psc">announcing a clinical trial delay</a>.</li>



<li>AgileThought (NASDAQ:<a href="https://investorplace.com/stock-quotes/agil-stock-quote/">AGIL</a>) stock is decreasing over 18% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317880221&amp;type=PDF&amp;symbol=AGIL&amp;cdn=9c2c8a730197e2b274fa81420856dd5c&amp;companyName=AgileThought+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-11-20">a delisting notice</a>.</li>



<li>Bruush Oral Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/brsh-stock-quote/">BRSH</a>) shares are falling more than 13% <a href="https://investorplace.com/2023/11/why-is-bruush-oral-care-brsh-stock-up-184-today/">after a rally yesterday</a>.</li>



<li>Vicarious Surgical (NYSE:<a href="https://investorplace.com/stock-quotes/rbot-stock-quote/">RBOT</a>) stock is slipping almost 13% on Tuesday morning.</li>



<li>Acutus Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/afib-stock-quote/">AFIB</a>) shares close out our pre-market stock movers down over 12% on Tuesday.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/11/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-nov-21st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Thursday morning and we have all the coverage traders need to know about today.



Moving stocks this morning are public offerings, earnings reports and more.



Let&rsquo;s dive into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>C3is (NASDAQ:<a href="https://investorplace.com/stock-quotes/ciss-stock-quote/">CISS</a>) stock is rocketing more than 54% with <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318003890&amp;type=PDF&amp;symbol=CISS&amp;cdn=9e68ec97a5e4417f3d8213dc120fc8ca&amp;companyName=C3is+Inc.&amp;formType=SC+13D%2FA&amp;formDescription=%5BAmend%5D+General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-01-24">investor stake updates</a> <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318003960&amp;type=PDF&amp;symbol=CISS&amp;cdn=5e8f74871313887e99068482c5f7ff30&amp;companyName=C3is+Inc.&amp;formType=SC+13D%2FA&amp;formDescription=%5BAmend%5D+General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-01-24">after a public offering</a>.</li>



<li>Charge Enterprises (NASDAQ:<a href="https://investorplace.com/stock-quotes/crge-stock-quote/">CRGE</a>) shares are soaring over 47% alongside heavy pre-market trading.</li>



<li>Onconetix (NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/">ONCO</a>) stock is surging more than 34% with strong early morning trading.</li>



<li>Acutus Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/afib-stock-quote/">AFIB</a>) shares are gaining close to 30% as it sees heavy trading on Thursday morning.</li>



<li>AgeX Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/age-stock-quote/">AGE</a>) stock is increasing over 24% on Thursday.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) shares are rising more than 21% today.</li>



<li>Sangoma Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sang-stock-quote/">SANG</a>) stock is climbing over 17% this morning.</li>



<li>GraniteShares 2x Short TSLA Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsdd-stock-quote/">TSDD</a>) shares are getting an almost 17% boost as Tesla (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>) reports <a href="https://www.cnbc.com/2024/01/24/tesla-tsla-earnings-q4-2023.html">weak auto revenue</a> and warns of slow growth in 2024.</li>



<li>American Superconductor (NASDAQ:<a href="https://investorplace.com/stock-quotes/amsc-stock-quote/">AMSC</a>) stock is jumping more than 16% after <a href="https://finance.yahoo.com/news/american-superconductor-amsc-q3-earnings-222004378.html">releasing its Q3 earnings report</a>.</li>



<li>T-Rex 2X Inverse Tesla Daily Target ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslz-stock-quote/">TSLZ</a>) shares are up over 15% alongside Tesla&rsquo;s financial news.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Akoustis Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/akts-stock-quote/">AKTS</a>) stock is crashing more than 26% with a <a href="https://www.nasdaq.com/press-release/akoustis-announces-proposed-public-offering-of-common-stock-2024-01-24">proposed public offering</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are plummeting over 22% on Thursday.</li>



<li>1847 (NYSEMKT:<a href="https://investorplace.com/stock-quotes/efsh-stock-quote/">EFSH</a>) stock is diving more than 19% with a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318003748&amp;type=PDF&amp;symbol=EFSH&amp;cdn=c0faa20ef68ea5dba06b270dbba0e018&amp;companyName=1847+Holdings+LLC&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-01-24">proposed public offering</a>.</li>



<li>CCC Intelligent Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/cccs-stock-quote/">CCCS</a>) shares are tumbling over 18% on Thursday.</li>



<li>OneMedNet (NASDAQ:<a href="https://investorplace.com/stock-quotes/onmd-stock-quote/">ONMD</a>) stock is taking a more than 16% beating today.</li>



<li>eFFECTOR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eftr-stock-quote/">EFTR</a>) shares are sliding over 15% without any clear news to report.</li>



<li>Humana (NYSE:<a href="https://investorplace.com/stock-quotes/hum-stock-quote/">HUM</a>) stock is dropping more than 15% with its <a href="https://www.barrons.com/articles/humana-earnings-stock-price-b206aae5">latest earnings reports</a>.</li>



<li>GraniteShares 2x Long TSLA Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslr-stock-quote/">TSLR</a>) shares are decreasing over 15% with TSLA earnings.</li>



<li>T-REX 2X Long Tesla Daily Target ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslt-stock-quote/">TSLT</a>) stock is falling more than 15% on Tesla earnings.</li>



<li>Columbia Banking System (NASDAQ:<a href="https://investorplace.com/stock-quotes/colb-stock-quote/">COLB</a>) shares close out our pre-market stock movers down over 14% after releasing its <a href="https://finance.yahoo.com/news/columbia-banking-colb-q4-earnings-230003496.html">Q4 earnings report</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-jan-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into on Tuesday as we check out all of the hottest news this morning!



Moving stocks are acquisition deals, new investments, earnings reports and more.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Fusion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/fusn-stock-quote/">FUSN</a>) stock is rocketing more than 95% as AstraZeneca (NASDAQ:<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>) is <a href="https://finance.yahoo.com/news/fusion-pharmaceuticals-acquired-astrazeneca-accelerating-070000564.html">acquiring it for $2.4 billion</a>.</li>



<li>Ontrak (NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/">OTRK</a>) shares are soaring over 75% alongside heavy pre-market trading.</li>



<li>Zoomcar (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcar-stock-quote/">ZCAR</a>) stock is surging more than 59% after <a href="https://www.nasdaq.com/press-release/easemytrip-partners-with-zoomcar-to-provide-pre-booked-and-on-demand-self-drive-cars">partnering with EaseMyTrip</a>.</li>



<li>Li-Cycle (NYSE:<a href="https://investorplace.com/stock-quotes/licy-stock-quote/">LICY</a>) shares are gaining over 23% on a <a href="https://finance.yahoo.com/news/li-cycle-provides-business-following-203000200.html">$75 million investment</a>.</li>



<li>XTI Aerospace (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtia-stock-quote/">XTIA</a>) stock is increasing more than 23% after <a href="https://www.prnewswire.com/news-releases/xti-aerospace-to-begin-trading-on-nasdaq-on-march-13-2024-302087343.html">going public last week</a>.</li>



<li>National CineMedia (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncmi-stock-quote/">NCMI</a>) shares are rising over 22% with a <a href="https://www.nasdaq.com/press-release/national-cinemedia-inc.-reports-results-for-fiscal-fourth-quarter-and-full-year-2023">Q4 earnings report</a> and <a href="https://www.nasdaq.com/press-release/national-cinemedia-inc.-announces-new-%24100-million-share-repurchase-program-2024-03">a share buyback</a>.</li>



<li>SCWorx (NASDAQ:<a href="https://investorplace.com/stock-quotes/worx-stock-quote/">WORX</a>) stock is heading more than 22% higher with strong trading on Tuesday morning.</li>



<li>Spire Global (NYSE:<a href="https://investorplace.com/stock-quotes/spir-stock-quote/">SPIR</a>) shares are climbing over 21% on <a href="https://www.nasdaq.com/press-release/spire-global-to-enhance-ai-driven-weather-prediction-in-collaboration-with-nvidia">a collaboration deal</a> with Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>).</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is jumping more than 17% as Walleye Capital LLC <a href="https://www.defenseworld.net/2024/03/19/chijet-motor-company-inc-nasdaqcjet-shares-acquired-by-walleye-capital-llc.html">bought more shares</a>.</li>



<li>MultiPlan (NYSE:<a href="https://investorplace.com/stock-quotes/mpln-stock-quote/">MPLN</a>) shares are up over 15% on Tuesday morning.</li>
</ol><h2>Top 10 Losers</h2>



<ol><li>Greenwave Tech Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/gwav-stock-quote/">GWAV</a>) stock is crashing more than 53% after sending <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318169478&amp;type=PDF&amp;symbol=GWAV&amp;cdn=6579b73adff7712377a0ffb7fdf9836c&amp;companyName=Greenwave+Technology+Solutions+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-03-18">warrant exercise inducement offer letters</a> to holders.</li>



<li>ShiftPixy (NASDAQ:<a href="https://investorplace.com/stock-quotes/pixy-stock-quote/">PIXY</a>) shares are plummeting over 33% after a recent surge in price.</li>



<li>Acutus Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/afib-stock-quote/">AFIB</a>) stock is diving more than 18% after rallying yesterday.</li>



<li>MIND C.T.I. (NASDAQ:<a href="https://investorplace.com/stock-quotes/mndo-stock-quote/">MNDO</a>) shares are tumbling over 17% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318167200&amp;type=PDF&amp;symbol=MNDO&amp;cdn=631f891b9f7743251ba890825825b205&amp;companyName=MIND+C.T.I.+Ltd.&amp;formType=20-F&amp;formDescription=Annual+and+transition+report+of+foreign+private+issuers+%5BSections+13+or+15%28d%29%5D&amp;dateFiled=2024-03-18">following a business update</a>.</li>



<li>Alpine 4 (NASDAQ:<a href="https://investorplace.com/stock-quotes/alpp-stock-quote/">ALPP</a>) stock is taking a more than 15% beating without any clear news this morning.</li>



<li>Palladyne AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/strc-stock-quote/">STRC</a>) shares are sliding over 15% <a href="https://www.businesswire.com/news/home/20240315028771/en/Sarcos-Robotics-is-Now-Palladyne-AI">after a name change</a> and planned ticker change.</li>



<li>Wearable Devices (NASDAQ:<a href="https://investorplace.com/stock-quotes/wlds-stock-quote/">WLDS</a>) stock is dropping more than 13% <a href="https://www.tradingview.com/news/benzinga:dad873646094b:0-why-wearable-devices-stock-is-shooting-higher/">following a Monday rally</a>.</li>



<li>Joann (NASDAQ:<a href="https://investorplace.com/stock-quotes/joan-stock-quote/">JOAN</a>) shares are decreasing over 13% following a <a href="https://investorplace.com/2024/03/why-is-joann-joan-stock-up-15-today/">recent bankruptcy filing</a>.</li>



<li>Kwesst Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is falling more than 12% despite a lack of news.</li>



<li>DLocal (NASDAQ:<a href="https://investorplace.com/stock-quotes/dlo-stock-quote/">DLO</a>) shares close out our pre-market stock movers down over 12% on <a href="https://markets.businessinsider.com/news/stocks/dlocal-posts-mixed-q4-results-joins-stoneco-beyond-meat-and-other-big-stocks-moving-lower-in-tuesday-s-pre-market-session-1033175560">mixed Q4 results</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-march-19th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Acutus Medical GAAP EPS of -$2.81, revenue of $7.2M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Monday!



Moving stocks this morning are acquisition agreements, delisting updates, earnings reports, results from a clinical trial and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Strong Global Entertainment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/sge-stock-quote/">SGE</a>) stock is rocketing more than 73% after <a href="https://www.nasdaq.com/press-release/fg-acquisition-corp.-announces-proposed-acquisition-of-strong-mdi-screen-systems-inc.">announcing an acquisition</a> deal for Strong/MDI Screen Systems.</li>



<li>Perficient (NASDAQ:<a href="https://investorplace.com/stock-quotes/prft-stock-quote/">PRFT</a>) shares are soaring over 52% on a <a href="https://www.nasdaq.com/press-release/perficient-to-be-acquired-by-eqt-for-approximately-%243.0-billion-2024-05-05">$3 billion acquisition agreement</a>.</li>



<li>Beneficient (NASDAQ:<a href="https://investorplace.com/stock-quotes/benf-stock-quote/">BENF</a>) stock is surging more than 30% as it continues to rally after <a href="https://investorplace.com/2024/05/why-is-beneficient-benf-stock-up-390-today/">regaining Nasdaq compliance</a>.</li>



<li>Holdco Nuvo Group DG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) shares are gaining close to 26% alongside heavy pre-market trading.</li>



<li>Ohmyhome (NASDAQ:<a href="https://investorplace.com/stock-quotes/omh-stock-quote/">OMH</a>) stock is increasing over 25% with strong early morning trading.</li>



<li>Graphex (NYSEMKT:<a href="https://investorplace.com/stock-quotes/grfx-stock-quote/">GRFX</a>) shares are rising more than 20% on Monday morning with heavy trading.</li>



<li>Kuke Music (NYSE:<a href="https://investorplace.com/stock-quotes/kuke-stock-quote/">KUKE</a>) stock is climbing 15% without any clear news this morning.</li>



<li>MagnaChip Semiconductor (NYSE:<a href="https://investorplace.com/stock-quotes/mx-stock-quote/">MX</a>) shares are heading almost 14% higher after <a href="https://www.msn.com/en-us/money/markets/mx-stock-earnings-magnachip-semiconductor-beats-eps-beats-revenue-for-q1-2024/ar-AA1o3Wvk?ocid=finance-verthp-feeds">beating Q1 estimates</a>.</li>



<li>XBP Europe (NASDAQ:<a href="https://investorplace.com/stock-quotes/xbp-stock-quote/">XBP</a>) stock is jumping over 13% despite a lack of news today.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) shares are up more than 12% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is crashing over 65% after releasing <a href="https://www.nasdaq.com/press-release/glycomimetics-announces-results-of-pivotal-phase-3-study-of-uproleselan-in-relapsed">Phase 3 clinical trial results</a>.</li>



<li>Acutus Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/afib-stock-quote/">AFIB</a>) shares are plummeting more than 37% as <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318290674&amp;type=PDF&amp;symbol=AFIB&amp;cdn=6e5e582e7483b6fb995c1c182a92e5fd&amp;companyName=Acutus+Medical+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-03">its delisting approaches</a>.</li>



<li>Meta Materials (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmat-stock-quote/">MMAT</a>) stock is diving over 27% on plans to <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318290809&amp;type=PDF&amp;symbol=MMAT&amp;cdn=0035f13ac51900fd0da1cc198df775b6&amp;companyName=Meta+Materials+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-03">lay off 80% of its employees</a>.</li>



<li>Loop Media (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) shares are falling more than 18% after releasing its <a href="https://www.nasdaq.com/press-release/loop-media-reports-2024-fiscal-second-quarter-financial-results-2024-05-03">fiscal Q2 2024 earnings report</a>.</li>



<li>Medical Properties Trust (NYSE:<a href="https://investorplace.com/stock-quotes/mpw-stock-quote/">MPW</a>) stock is tumbling over 18% after tenant Steward Health <a href="https://www.marketwatch.com/story/medical-properties-trust-shares-drop-on-steward-health-bankruptcy-d1c76635?mod=investing">filed for bankruptcy</a>.</li>



<li>Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) shares are dropping more than 16% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318292604&amp;type=PDF&amp;symbol=POAI&amp;cdn=be2400ae57b9aff8b086174983e0993c&amp;companyName=Predictive+Oncology+Inc.&amp;formType=S-3&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-05-06">proposed public offering</a>.</li>



<li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock is taking an over 16% beating on Monday morning.</li>



<li>Benson Hill (NYSE:<a href="https://investorplace.com/stock-quotes/bhil-stock-quote/">BHIL</a>) shares are sliding more than 15% with strong trading this morning.</li>



<li>Mobile-health Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/mndr-stock-quote/">MNDR</a>) stock is decreasing over 14% today.</li>



<li>NeuBase Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nbse-stock-quote/">NBSE</a>) shares are down 13% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318290536&amp;type=PDF&amp;symbol=NBSE&amp;cdn=0bee8495da7c92b56ecafb96c97b1e73&amp;companyName=NeuBase+Therapeutics+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-03">another delisting notice</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-may-6th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Acutus Medical&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/afib-stock-quote/">AFIB</a>) stock is falling hard on Monday as investors prepare for the arrhythmias&nbsp;tool development company&rsquo;s <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318290674&amp;type=PDF&amp;symbol=AFIB&amp;cdn=6e5e582e7483b6fb995c1c182a92e5fd&amp;companyName=Acutus+Medical+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-03">delisting later this week</a>.



AFIB stock is being delisted due to its inability to reach the minimum bid price of $1 per share on the Nasdaq Exchange. In addition to that, the company has failed to maintain a stockholder equity of at least $2.5 million. That&rsquo;s another cause for delisting.



Investors will note that Acutus Medical has no avenue to avoid this delisting. The company has already used up both of its 180-day extensions in an effort to regain compliance. As a result, its shares will stock trading on the Nasdaq Exchange starting on Thursday.



<h2>What&rsquo;s Next for AFIB Stock?</h2>



Acutus Medical has no intention of appealing the Nasdaq&rsquo;s decision and accepts the delisting. The company expects its shares to start trading on the OTC Pink Sheets once it is delisted from the Nasdaq. It also intends to create new trading opportunities but says there&rsquo;s no guarantee this will happen.



AFIB stock is down 40.6% as of Monday morning. That builds on a 31.1% drop year-to-date when markets last closed. It&rsquo;s also worth noting that some 439,000 shares have traded so far today, as compared to a daily average of about 1 million shares.



Investors will find all of the latest stock market stories worth reading about today!



We have all of that news available for traders on Monday! That includes everything happening with shares of GlycoMimetics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock, Perficient&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/prft-stock-quote/">PRFT</a>)&nbsp;stock and Strong Global&nbsp;Entertainment&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/sge-stock-quote/">SGE</a>) stock today. All of that info is available at the links below!



<h2>More Stock Market News for Monday</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-glycomimetics-glyc-stock-down-77-today/">Why Is GlycoMimetics (GLYC) Stock Down 77% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-perficient-prft-stock-up-53-today/">Why Is Perficient (PRFT) Stock Up 53% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-strong-global-entertainment-sge-stock-up-58-today/">Why Is Strong Global Entertainment (SGE) Stock Up 58% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-acutus-medical-afib-stock-down-41-today/">Why Is Acutus Medical (AFIB) Stock Down 41% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Acutus Medical (AFIB) Stock Down 41% Today?

Acutus Medical GAAP EPS of -$0.06, revenue of $3.6M

ADXN

AGIL

AKTS

ALPP

ALZN

AMSC

AORT

BBLG

BENF

BHIL

BIVI

BRSH

CCCS

CISS

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Acutus Medical

Acutus Medical (AFIB) Forecast

Acutus Medical (OTC:AFIB) Stock, Quote.Headers.trade-ideas